KTE-C19 granted Priority Review by the FDA for the treatment of relapsed/refractory Non-Hodgkin Lymphoma patients ineligible for transplant | LymphomaHub

KTE-C19 granted Priority Review by the FDA for the treatment of relapsed/refractory Non-Hodgkin Lymphoma patients ineligible for transplant | LymphomaHub

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s